全文获取类型
收费全文 | 42373篇 |
免费 | 2739篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 645篇 |
儿科学 | 1028篇 |
妇产科学 | 649篇 |
基础医学 | 5083篇 |
口腔科学 | 609篇 |
临床医学 | 4752篇 |
内科学 | 8483篇 |
皮肤病学 | 545篇 |
神经病学 | 3710篇 |
特种医学 | 1566篇 |
外国民族医学 | 2篇 |
外科学 | 6828篇 |
综合类 | 518篇 |
一般理论 | 51篇 |
预防医学 | 4054篇 |
眼科学 | 736篇 |
药学 | 3146篇 |
中国医学 | 42篇 |
肿瘤学 | 2778篇 |
出版年
2023年 | 297篇 |
2022年 | 560篇 |
2021年 | 1270篇 |
2020年 | 749篇 |
2019年 | 1137篇 |
2018年 | 1333篇 |
2017年 | 938篇 |
2016年 | 972篇 |
2015年 | 1171篇 |
2014年 | 1746篇 |
2013年 | 2281篇 |
2012年 | 3272篇 |
2011年 | 3335篇 |
2010年 | 1765篇 |
2009年 | 1626篇 |
2008年 | 2814篇 |
2007年 | 2722篇 |
2006年 | 2499篇 |
2005年 | 2548篇 |
2004年 | 2337篇 |
2003年 | 2111篇 |
2002年 | 1961篇 |
2001年 | 384篇 |
2000年 | 370篇 |
1999年 | 412篇 |
1998年 | 388篇 |
1997年 | 304篇 |
1996年 | 296篇 |
1995年 | 230篇 |
1994年 | 224篇 |
1993年 | 185篇 |
1992年 | 220篇 |
1991年 | 197篇 |
1990年 | 215篇 |
1989年 | 166篇 |
1988年 | 169篇 |
1987年 | 156篇 |
1986年 | 128篇 |
1985年 | 145篇 |
1984年 | 137篇 |
1983年 | 124篇 |
1982年 | 130篇 |
1981年 | 87篇 |
1980年 | 66篇 |
1979年 | 99篇 |
1978年 | 86篇 |
1975年 | 67篇 |
1973年 | 69篇 |
1972年 | 61篇 |
1969年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
Erin A. McClure Nathaniel L. Baker Kevin M. Gray 《The American journal of drug and alcohol abuse》2014,40(4):285-291
Background and objectives: Tobacco and cannabis use are both highly prevalent worldwide. Their co-use is also common in adults and adolescents. Despite this frequent co-occurrence, cessation from both substances is rarely addressed in randomized clinical trials. Given evidence that tobacco use may increase during cannabis cessation attempts, and additionally that tobacco users have poorer cannabis cessation outcomes, we explored tobacco outcomes, specifically cigarette smoking, from an adolescent cannabis cessation trial that tested the efficacy of N-acetylesteine (NAC). Methods: Cannabis-dependent adolescents (ages 15–21; n?=?116) interested in cannabis treatment were randomized to NAC (1200?mg bid) or matched placebo for 8 weeks. Participants did not need to be cigarette smokers or be interested in smoking cessation to qualify for inclusion. Results: Approximately 59% of enrolled participants were daily and non-daily cigarette smokers, and only differed from non-smoking participants on the compulsion sub-scale of the Marijuana Craving Questionnaire. Among cigarette smokers who were retained in the study, there was no change in cigarettes per day for either NAC or placebo groups during the eight-week treatment phase. Being a cigarette smoker did not appear to influence the effects of NAC on cannabis abstinence, though there was a trend in the placebo group of poorer cannabis outcomes for cigarette smokers vs. non-smokers. Conclusions: No evidence was found of compensatory cigarette smoking during this cannabis cessation trial in adolescents. Further work assessing interventions to reduce both cannabis and tobacco use in this population is greatly needed. 相似文献
994.
995.
Elizabeth T. Jensen PhD Alain G. Bertoni MD Osa L. Crago BS Kristi L. Hoffman PhD Alexis C. Wood PhD Zorayr Arzumanyan BS Lok-Sze Kelvin Lam BSc Kathryn Roll RN Kevin Sandow BS Martin Wu PhD Stephen S. Rich PhD Jerome I. Rotter MD Yii-Der I. Chen PhD Joseph F. Petrosino PhD Mark O. Goodarzi MD 《Diabetes, obesity & metabolism》2020,22(11):1976-1984
996.
997.
998.
999.
1000.
Andrew D. Watt Gabriela A. N. Crespi Russell A. Down David B. Ascher Adam Gunn Keyla A. Perez Catriona A. McLean Victor L. Villemagne Michael W. Parker Kevin J. Barnham Luke A. Miles 《Acta neuropathologica》2014,127(6):803-810
Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer’s disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting Aβ is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab. We have synthesized these antibodies and used surface plasmon resonance (SPR) and mass spectrometry to characterize and compare the ability of these antibodies to target Aβ in transgenic mouse tissue as well as human AD tissue. SPR analysis showed that the antibodies were able to bind Aβ with high affinity. All of the antibodies were able to bind Aβ in mouse tissue. However, significant differences were observed in human brain tissue. While bapineuzumab was able to capture a variety of N-terminally truncated Aβ species, the Aβ detected using solanezumab was barely above detection limits while crenezumab did not detect any Aβ. None of the antibodies were able to detect any Aβ species in human blood. Immunoprecipitation experiments using plasma from AD subjects showed that both solanezumab and crenezumab have extensive cross-reactivity with non-Aβ related proteins. Bapineuzumab demonstrated target engagement with brain Aβ, consistent with published clinical data. Solanezumab and crenezumab did not, most likely as a result of a lack of specificity due to cross-reactivity with other proteins containing epitope overlap. This lack of target engagement raises questions as to whether solanezumab and crenezumab are suitable drug candidates for the preventative clinical trials for AD. 相似文献